| Study Period | 2019 - 2032 |
| Market Size in 2024 | USD 3.3 billion |
| Market Size in 2025 | USD 3.5 billion |
| Market Size by 2032 | USD 5.3 billion |
| Projected CAGR | 6.2% |
| Largest Region | North America |
| Fastest Growing Region | Europe |
| Market Structure | Fragmented |
|
Explore the market potential with our data-driven report
The global hemostats market size was USD 3.3 billion in 2024, and the market size is predicted to reach USD 5.3 billion by 2032, advancing at a CAGR of 6.2% during 2025–2032.
The market is popular as surgical procedures keep growing and medical professionals place greater importance on effective blood management during surgery. The critical nature of hemostats enables bleeding control while shortening surgery durations which ultimately results in better treatment success for patients in contemporary surgical practice. The market undergoes two key developments with advanced bioabsorbable and biocompatible materials as hemostatic agents become more prevalent and increased usage of minimally invasive surgeries requiring enhanced bleeding control tools. Hemostatic products with antimicrobial functionality stand as a fast-growing segment in the market.
The market implements new technological approaches to enhance the effectiveness and security of these products. The hemostats market demonstrates positive market prospects as emerging economies develop their healthcare infrastructure and surgeons require more advanced surgical capabilities. Continuous research and development activities coupled with strategic partnerships between important market participants will drive the expansion of hemostatic applications throughout clinical settings while accelerating market growth
The orthopedic surgery category held the largest market share, of 75%, in 2024, because many medical procedures on bones joints, and soft tissues need reliable bleeding control. The increasing number of elderly patients, the higher cases of osteoporosis and arthritis drive continuous orthopedic intervention needs.
Hospitals along with surgical centers identify efficient bleeding control as vital during surgery which makes hemostats fundamental for better patient results and shorter recovery times after orthopedic procedures. Orthopedic surgery maintains its position as the primary application because both developed and developing nations require it consistently.
The cardiovascular surgery category will grow at a highest CAGR during the forecast period. This is because healthcare providers conduct complex procedures that frequently present critical bleeding risks to treat the global increase in cardiovascular diseases. Bypass grafting valve replacements and aortic repairs require exact and prompt blood control through hemostasis measures to avoid fatal results. Medical institutions focus on acquiring innovative blood control agents because cardiac procedures involving senior patients continue to increase. Specialized hemostatic materials have gained more popularity due to the rise of minimally invasive and hybrid cardiovascular interventions thus propelling growth.
The applications analyzed here are:
The thrombin-based hemostats category held the largest market share, of 70%, in 2024. This is because they create effective clots quickly. Surgical clots achieve rapid stabilization through thrombin which accelerates the conversion of fibrinogen into fibrin thus reducing surgical blood loss. The surgical procedures of cardiovascular alongside orthopedic and general surgeries have made these products an established clinical norm because of their broad use across different procedures.
Doctors prefer these hemostats in high-risk procedures because they rapidly work in coagulation disorder patients. Recombinant thrombin development has solved safety and immunogenicity concerns which has enhanced both adoption rates and the market leadership position of these products.
The collagen-based hemostats category will grow at a highest CAGR during the forecast period, because these products exhibit excellent biocompatibility alongside absorbability and natural clot formation capabilities. Bovine and porcine tissue procurements serve as the basic components to create these hemostats which work best during soft tissue and bone surgical procedures such as neurological work, reconstructive surgery, and dental procedures. Collagen supports platelet aggregation and adhesion because of its natural structure, thus demonstrating remarkable success in hemostasis promotion. The market demand for collagen-based hemostats keeps increasing because modern surgical practices continue to adopt biocompatible and biodegradable solutions.
The product types analyzed here are:
The sponge hemostats category held the largest market share, of 60%, in 2024. This is because they offer easy-to-use and high absorption ability along with effective results for diverse surgical procedures. The sponge-based hemostatic formulation consists of gelatin or collagen materials which create a physical matrix for blood clot formation before completely dissolving inside the body. The medical community selects these products for different surgical spaces such as deep or irregular wounds because they demonstrate excellent adaptability. Surgeons select these products because these products can fit around tissue surfaces and stop bleeding in targeted areas during procedures that need precise control with minimal disruption.
The powder hemostats category will grow at a highest CAGR during the forecast period, because these substances demonstrate superior application flow along with convenience for minimally invasive surgeries and laparoscopic procedures. This type of formulation provides excellent distribution properties for widespread or difficult-to-access bleeding sites thus enabling their effective usage during surgical procedures where pads and sponges prove ineffective. Minimal invasive surgeries now require powder-based hemostats because of their superior precision and ability to form smaller incisions which has driven their market demand upward.
The formulations analyzed here are:
The hospital's category held the largest market share, of 65%, in 2024. The facilities in these hospitals use advanced surgical infrastructure to support multiple specialties like general surgery and cardiovascular orthopedic and neurological units where hemostatic agents perform frequently. Hospitals maintain budgetary control to purchase all types of hemostats from both combination and thrombin-based categories. The dual role of hemostats in scheduled and urgent operations increases their demand because surgeons need them to control bleeding during surgery while enhancing treatment success rates. The teaching and research affiliation of hospitals makes them adopt new technologies first because of their advanced capabilities.
The ambulatory centers category will grow at a highest CAGR during the forecast period. This is because health systems currently focus on outpatient care and minimally invasive surgical procedures. The healthcare facilities serve patients and systems effectively through their provision of efficient same-day surgical operations at cost-effective prices. Hemostats with compact designs easy operation and fast performance now experience increased demand since they help reduce operative durations and also accelerate patient recovery times.
The end users analyzed here are:
Drive strategic growth with comprehensive market analysis
The North America held the largest market share, of 40%, in 2024. This is because it has both advanced medical facilities and extensive yearly surgical operations. The U.S. leads the market demand for advanced surgical products because it has both an aging demographic and many people who suffer from cardiovascular diseases and cancer. The region's leading position in the market stems from beneficial reimbursement systems together with robust regulatory backing and dominant participation of companies such as Baxter, Johnson & Johnson, and Medtronic. The market leadership position of the region in global hemostats is strengthened by its ability to quickly incorporate innovation and its access to qualified medical staff.
The European region will grow at a highest CAGR during the forecast period because surgical procedure numbers are rising healthcare investments are growing and physicians across multiple specialties are adopting advanced hemostatic products. The population growth coupled with strong public healthcare supports the use of high-quality medical products in this region. Countries like Germany, France, and U.K. lead this market expansion through their rising emergency and elective medical procedures. Furthermore, Germany is a key market in the region.
This is owing to the rise in healthcare spending in the country and the rising awareness about the use of hemostatic agents, adhesives, and tissue sealants to avoid the risk of postoperative bleeding. Moreover, the increasing demand for more effective and quicker healing post-surgery propels the market. The European drive toward eco-friendly materials that are safe for use in the body matches new safety and environmental standards which boost market demand. Government support combined with innovation-friendly regulations maintains market acceleration across the whole region. Additionally, the market in France is expected to witness notable growth during the forecast period. This can be attributed to the improving healthcare infrastructure, presence of major market players, increasing prevalence of chronic diseases, rising use of these products in surgical procedures, and surging count of initiatives by healthcare organizations to incorporate these solutions in their everyday practice.
The regions analyzed in this report are:
The hemostats market is fragmented because multiple global and regional companies present various products that match specific surgical requirements. It results from multiple surgical specialties and continuous innovation from smaller companies developing new hemostatic technologies. The market for hemostats extends widely throughout general surgery and cardiovascular procedures together with orthopedic and neurological interventions since the world has experienced growing surgical needs and better minimally invasive surgical approaches.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages